Arvinas: Phase 1 Parkinson's trial data shows ARV-102 linked gains in oculomotor measure

Arvinas presented final Phase 1 data on ARV-102 in Parkinson’s disease, supporting CNS exposure, LRRK2 degradation, and improved objective eye-movement function. Biomarker shifts were consistent with disease-relevant pathway modulation, and exploratory analyses linked biomarker reductions with eye-movement changes.